<DOC>
	<DOCNO>NCT01584843</DOCNO>
	<brief_summary>Primary objective evaluate efficacy single-dose treatment GSK1358820 compare non-treatment patient strabismus base angle strabismus primary position .</brief_summary>
	<brief_title>Efficacy Safety GSK1358820 ( Botulinum Toxin Type A ) Patients With Strabismus</brief_title>
	<detailed_description>Primary objective evaluate efficacy single-dose treatment GSK1358820 compare non-treatment patient strabismus base angle strabismus primary position . Secondary objective evaluate efficacy safety repeated-dose treatment GSK1358820 patient strabismus .</detailed_description>
	<mesh_term>Strabismus</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>&lt; At start screen period &gt; Paralytic concomitant strabismus . Subjects paralytic strabismus eligible inclusion paralysis persist least 3 month strabismus develop one eye Horizontal deviation ( esotropia exotropia ) Strabismus ( absolute ) strabismus angle distance near primary position &gt; 10 PD &lt; 50 PD Age &gt; 12 year time give informed consent The subject capable give write informed consent . For subject age less 20 year , subject his/her legally acceptable representative ( person parental authority guardian ) give write informed consent Either sex . Males agree practice contraception study period . Females childbearing potential eligible inclusion study . However , negative pregnancy test screen visit initial injection agree practice reliable method contraception QTc &lt; 450 msec ; patient Bundle Branch Block , QTc &lt; 480 msec base average QTc value triplicate ECGs &lt; At start treatment period &gt; Strabismus ( absolute ) strabismus angle distance near primary position &gt; 10 PD &lt; 50 PD ALT screen visit &lt; 2 x ULN alkaline phosphatase bilirubin &lt; 1.5 x ULN &lt; At start screen period &gt; Secondary strabismus cause prior surgical recession antagonist past surgical treatment strabismus Strabismus due abnormal innervation Strabismus thyroidassociated ophthalmopathy Strabismus strong motor limitation extraocular muscle Mechanical limitation ocular movement due periorbital disease due past surgical treatment strabismus Blepharoptosis Conjunctival pathology Systemic neuromuscular junction dysfunction Systemic neuromuscular disease Past treatment botulinum toxin Planned injection botulinum toxin indication ( ) cosmetic purpose study period Known hypersensitivity drug use study history allergy Treatment antibiotic neuromuscular junction inhibitory action aminoglycosides , polypeptide , tetracycline lincomycin , except contain topical antibacterial formulation Treatment muscle relaxant drug muscle relaxant action Chronic respiratory disorder Severe muscle weakness atrophy Angleclosure glaucoma predispose factor Severe cardiac , hepatic renal impairment . The severity refers Grade 3 accord `` Classification Severity Adverse Experiences '' ( MHLW PAB/SD Notification No . 80 , date 29 June 1992 ) . Surgical operation hospitalization need study period Female subject pregnant lactating , may pregnant , plan pregnancy study period Participation another clinical study within 6 month prior enrollment study plan participation another clinical study enrollment study Psychiatric disorder impairment intellectual function may affect subject 's ability give inform consent comply trial procedure History alcohol dependence drug abuse Subjects investigator ( subinvestigator ) considers ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neuromuscular Agents</keyword>
	<keyword>Strabismus</keyword>
	<keyword>Botulinum Toxin Type A</keyword>
</DOC>